Issues
-
Cover Image
Cover Image
Galectin-1, a carbohydrate-binding protein, abundantly expressed at sites of tumor growth and metastasis, promotes tumor progression by influencing diverse cancer-related events including tumor cell migration, angiogenesis, and tumor-immune escape. Dalotto-Moreno and colleagues show that galectin-1 contributes to immunosuppression during progression of breast cancer. Human breast cancer biopsies expressed substantial amounts of galectin-1, which positively correlated with tumor grade. Silencing Gal1 expression in the 4T1 breast tumor model reduced tumor growth and lung metastases. This effect was accompanied by a diminished frequency and suppressive activity of CD4+CD25+ Foxp3+ regulatory T cells in both the tumor and metastatic lungs. For details, see article by Dalotto-Moreno and colleagues on page 1107. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
Meeting Report
Priority Reports
Clinical Studies
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
Integrated Systems and Technologies
Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms
Microenvironment and Immunology
Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis
Targeting Galectin-1 Overcomes Breast Cancer-Associated Immunosuppression and Prevents Metastatic Disease
Inhibition of Rapamycin-Induced AKT Activation Elicits Differential Antitumor Response in Head and Neck Cancers
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
Molecular and Cellular Pathobiology
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Therapeutics, Targets, and Chemical Biology
Tumor and Stem Cell Biology
Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
Tumor Suppressor Function of the Plasma Glutathione Peroxidase Gpx3 in Colitis-Associated Carcinoma
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.